Skip Navigation LinksHome > January 2014 - Volume 18 - Issue 1 > HPV Testing and Vaccination in Europe
Journal of Lower Genital Tract Disease:
doi: 10.1097/LGT.0b013e318286b8d3
Original Articles

HPV Testing and Vaccination in Europe

Leeson, Simon C. FRCS, FRCOG1; Alibegashvili, Tamar MD, PhD2; Arbyn, Marc MD, MSc, DrTMH3; Bergeron, Christine MD, PhD4; Carriero, Carmine MD, PhD5; Mergui, Jean-Luc MD6; Nieminen, Pekka MD, PhD7; Prendiville, Walter FRCOG8; Redman, Charles W.E. MD9; Rieck, Gudrun C. MD1; Quaas, Jens MD10; Petry, K. Ulrich MD, PhD11

Collapse Box

Abstract

Abstract: Current cytology-based screening has a moderate sensitivity to detect cervical intraepithelial neoplasia grade 3 (CIN 3) and cervical cancer even in those states providing rigorous quality control of their cervical screening programs. The impact of vaccination against human papillomavirus (HPV) types 16 and 18 as well as the incorporation of HPV testing on the detection of CIN 3 and cancer is discussed. HPV testing used as a triage for atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions, test of cure after treatment, and HPV-based primary screening may improve current cervical screening programs.

HPV testing as a triage test for ASCUS seems to offer an improved sensitivity, with a similar specificity as compared to repeat cytology for diagnosing high-grade CIN and has been recommended throughout most EU states. HPV testing as a triage test for low-grade squamous intraepithelial lesions has a low specificity and is not recommended in most member states. HPV test of cure offers an improved sensitivity compared to cytology for women with persistent cervical precancer after treatment. HPV-based cervical cancer screening is more effective than screening with cytology. The effects of HPV-based screening depend on the organization of the program and on adherence to algorithms for screening triage. Otherwise, it is likely that HPV-based screening will increase the referral rate to colposcopy including more women with no detectable cervical lesion. HPV vaccination will require many years to evaluate any beneficial effects on cervical cancer incidence and mortality.

Copyright © 2014 by the American Society for Colposcopy and Cervical Pathology

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.